Habif TP. Psoriasis and other papulosquamous diseases. In: Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 5th ed. Pennsylvania: Mosby, Elsevier; 2010.
Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab): highlights of prescribing information. Novartis. http://www.pharma.us.novartis.com/product/pi/pdf/cosentyx.pdf. Jan 2015. Accessed 30 Jan 2015.
U.S. Food & Drug Administration. FDA approves new psoriasis drug Cosentyx. US FDA. http://www.fda.gov/. 21 Jan 2015. Accessed 30 Jan 2015.
Ministry of Health Malaysia, Dermatological Society of Malaysia, Academy of Medicine Malaysia. Clinical practice guidelines. Management of psoriasis vulgaris. Academy of Medicine of Malaysia. http://www.acadmed.org.my/index.cfm?&menuid=67#Skin_Condition. Jun 2013. Accessed 24 Mar 2016.
Nast A, Gisondi P, Ormerod AD, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris - update 2015 - short version - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-2294. doi: 10.1111/jdv.13354. Accessed 06 Apr 2016. PMID: 26481193
Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017 Sep;177(3):628-636. doi: 10.1111/bjd.15665. Accessed 29 Jun 2017. PMID: 28513835
Nast A, Boehncke WH, Mrowietz U, et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012 Mar;10(Suppl 2):S1-S95. doi: 10.1111/j.1610-0387.2012.07919.x. PMID: 22386073
Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Accessed 04 Apr 2019. PMID: 30773097
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Accessed 04 April 2019. PMID: 30772098
National Institute for Health and Care Excellence (NICE). Dimethyl fumarate for treating moderate to severe plaque psoriasis. NICE. http://www.nice.org.uk. Sep 2017. Accessed 10 April 2019.
Dermatologicals. WHO Collaborating Centre for Drug Statistics Methodology. https://www.whocc.no/atc_ddd_index. 14 Dec 2021. Accessed 09 Feb 2022.
Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2461-2498. doi: 10.1111/jdv.16915. PMID: 33349983
Pai SB, Shetty S. Guidelines for bath PUVA, bathing suit PUVA and soak PUVA. Indian J Dermatol Venereol Leprol. Nov-Dec 2015;81(6):559-567. doi: 10.4103/0378-6323.168336. PMID: 26515832
Verallo-Rowell VM, Katalbas SS, Evangelista MTP, et al. Review update on topical therapy for psoriasis. Curr Derm Rep. 2018;7:24-36. https://doi.org/10.1007/s13671-018-0209-x.
Finnish Medical Society Duodecim. Psoriasis. In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2005 May.
Budamakuntla L, Shree-Lakshmi HV, Bansal A, et al. Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India. Psoriasis (Auckl). 2019;9:19-27. doi: 10.2147/PTT.S154073. PMID: 31119094
Feldman SR. Treatment of psoriasis in adults. UpToDate. https://www.uptodate.com. 30 Jun 2023.
Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017 Nov;76(11):1890-1896. doi: 10.1136/annrheumdis-2017-211384. PMID: 28814432
Electronic Medicines Compendium (EMC). British Association of Dermatologists patient information leaflet | Certolizumab pegol. EMC. https://www.medicines.org.uk/. 27 Jul 2022.
Gordon KB, Warren RB, Gottlieb AB, et al. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). Br J Dermatol. 2021 Apr;184(4):652-662. doi: 10.1111/bjd.19393. PMID: 32652544
Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. . 2018 Aug;79(2):302-314.e6. doi: 10.1016/j.jaad.2018.04.012. Accessed 28 Oct 2024. PMID: 29660421
Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2):228-233. doi: 10.1136/annrheumdis-2017-212196. PMID: 29030361
Strober B, Paul C, Blauvelt A, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023 Sep;89(3):486-495. doi: 10.1016/j.jaad.2023.04.063. Accessed 28 Oct 2024. PMID: 37182701
Blauvelt A, Iversen L, McBride S, et al. Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial. SKIN The Journal of Cutaneous Medicine. 2021 Nov;5:s52. doi: s53. 10.25251/skin.5.supp.53.
Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021 Feb;397(10273):1182. doi: 10.1016/S0140-6736(21)00669-3. PMID: 33549192
Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 Feb;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2. Accessed 28 Oct 2024. PMID: 33549193
Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021 Jul;385(2):130-141. doi: 10.1056/NEJMoa2102388. Accessed 28 Oct 2024. PMID: 33891379
Blauvelt A, Foley P, Langley R, et al. Bimekizumab 4-year maintenance of responses in week 16 responders with moderate to severe plaque psoriasis: results from the BE BRIGHT open label extension phase 3 trial. Journal of the American Academy of Dermatology. 2024 Sep;91(3):AB23. doi: 10.1016/j.jaad.2024.07.102.
National Health Service (NHS). Clinical protocol: treatment pathway for adults with moderate to severe psoriasis. NHS. https://www.nhs.uk/. Aug 2024.
Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update. Br J Dermatol. 2024 Jan;190(2):270-272. doi: 10.1093/bjd/ljad347. PMID: 37740557
Feldman SR, Lewitt GM. Chronic plaque psoriasis in adults: treatment of disease amenable to topical therapy. UpToDate. https://www.uptodate.com. 16 Jun 2025.
Feldman SR, Soung J. Chronic plaque psoriasis in adults: treatment of disease requiring phototherapy or systemic therapy. UpToDate. https://www.uptodate.com. 15 Oct 2025.
Nast A, Spuls PI, Dressler C, et al. EuroGuiDerm guideline for the systemic treatment of psoriasis vulgaris: European Dermatology Forum. European Dermatology Forum. https://www.guidelines.edf.one. Feb 2025.
World Health Organization (WHO). Global report on psoriasis. WHO. https://www.who.int/. 2016.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019 Mar;20(6):1475. doi: 10.3390/ijms20061475. PMID: 30909615
Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017 Sep;140(3):645-653. doi: 10.1016/j.jaci.2017.07.004. PMID: 28887948
Feldman SR. Psoriasis: epidemiology, clinical manifestations, and diagnosis. UpToDate. https://www.uptodate.com. 26 Nov 2024. Accessed 24 Apr 2023.
Blauvelt A, Ehst BD. Pathophysiology of plaque psoriasis. UpToDate. https://www.uptodate.com. 12 Oct 2021.
U.S. Food & Drug Administration (US FDA). Abrilada highlights of prescribing information. US FDA. https://www.fda.gov/. Nov 2019. Accessed 18 Aug 2022.
Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020 Jun;82(6):1445-1486. doi: 10.1016/j.jaad.2020.02.044. Accessed 09 Dec 2020. PMID: 32119894
Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2020 Jul:S0190-9622(20)32288-X. doi: 10.1016/j.jaad.2020.07.087. Accessed 09 Dec 2020. PMID: 32738429
Smith CH, Yiu ZZ, Bale T, et al; British Association of Dermatologists’ Clinical Standards Unit. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update. Br J Dermatol. 2020 Oct;183(4):628-637. doi: 10.1111/bjd.19039. Accessed 05 Jun 2020. PMID: 32189327
Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019 Sep;81(3):775-804. doi: 10.1016/j.jaad.2019.04.042. Accessed 04 Feb 2020. PMID: 31351884
U.S. Food & Drug Administration (US FDA). Biosimilar product information. US FDA. https://www.fda.gov/. 24 Feb 2020. Accessed 28 Feb 2020.
Feldman SR. Epidemiology, clinical manifestations, and diagnosis of psoriasis. UpToDate. http://www.uptodate.com. Jul 2017. Accessed 28 May 2018.
Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013 May;87(9):626-633. https://www.aafp.org/. Accessed 28 May 2018. PMID: 23668525
National Institute for Health and Care Excellence (NICE). Apremilast for treating moderate to severe plaque of psoriasis. NICE. http://www.nice.org.uk/. Nov 2016. Accessed 28 May 2018.
Nast A, Spuls PI, van der Kraaij G, et al. European S3-guideline on the systemic treatment of psoriasis vulgaris – update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1951-1963. doi: 10.1111/jdv.14454. Accessed 28 May 2018. PMID: 28895202
Feldman SR. Treatment of psoriasis in adults. UpToDate. http://www.uptodate.com/. Nov 2017. Accessed 28 May 2018.
American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-174. doi: 10.1016/j.jaad.2010.11.055. PMID: 21306785
National Institute for Health and Clinical Excellence (NICE). Ustekinumab for the treatment of adults with moderate to severe psoriasis. NICE. http://www.nice.org.uk. Sep 2009.
National Psoriasis Foundation. Psoriasis severity. National Psoriasis Foundation. http://www.psoriasis.org. 2013. Accessed 19 Jul 2013.
National Institute for Health and Clinical Excellence (NICE). Psoriasis: the assessment and management of psoriasis. NICE. http://www.nice.org.uk. Oct 2012.
National Institute for Health and Clinical Excellence (NICE). Infliximab for the treatment of adults with psoriasis. NICE. http://www.nice.org.uk. Jan 2008.
British Association of Dermatologists. Psoriasis guideline. British Association of Dermatologists. http://www.bad.org.uk. 2006. Accessed 07 Nov 2006.
Feldman SR. Epidemiology, pathophysiology, clinical manifestations, and diagnosis of psoriasis. UpToDate. http://www.uptodate.com/index. Dec 2010. Accessed 25 Apr 2011.
National Institute for Health and Clinical Excellence (NICE). Etanercept and efalizumab for the treatment of adults with psoriasis. NICE. http://www.nice.org.uk. Jul 2006.
Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of psoriasis and psoriatic arthritis in adults. SIGN. http://www.sign.ac.uk. 2010.
Ministry of Malaysia, Dermatological Society of Malaysia, Academy of Medicine Malaysia. Management of psoriasis. Second edition. Academy of Medicine Malaysia. https://www.acadmed.org.my. 2024.
National Institute for Health and Clinical Excellence (NICE). Adalimumab for the treatment of adults with psoriasis. NICE. http://www.nice.org.uk. Jun 2008.
Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. Toronto Dermatology Centre. http://www.torontodermatologycentre.com. Aug 2011. Accessed 19 Jul 2013.
Trehan M, Taylor CR. Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol. 2002 Nov;47(5):701-708. http://www.ncbi.nlm.nih.gov/pubmed/?term=12399761. PMID: 12399761
Zeichner JA, Lebwohl MG, Menter A, et al. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis. 2010 Sep;86(3 Suppl):5-31. PMID: 21049712
Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician. 2000 Feb;61(3):725-733, 736. https://www.aafp.org. PMID: 10695585
Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005 Sep;153(3):486-497. http://www.ncbi.nlm.nih.gov/pubmed/?term=16120132. PMID: 16120132
Ortonne JP, Humbert P, Nicolas JP, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 mcg g -1 ointment and calcipotriol 50 mcg g -1 ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol. 2003 Feb;148(2):326-333. http://www.ncbi.nlm.nih.gov/pubmed/?term=Ortonne++JP%2C+Humbert++P%2C++Nicolas++JP%2C+et++al%09%22Intra-individual+comparison+of+the+cutaneous+safety+and+efficacy+of+calcitriol+3+mcg+g+-1++ointment+and+calcipotriol+50+mcg+g+-1+ointment+on+chronic++plaque+. PMID: 12588387
Mudigonda T, Dabade TS, West CE, et al. Therapeutic modalities for localized psoriasis: 308-nm UVB excimer laser versus nontargeted phototherapy. Cutis. 2012 Sep;90(3):149-154. http://www.ncbi.nlm.nih.gov/pubmed/?term=23094316. PMID: 23094316
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010 Jan;62(1):114-135. doi: 10.1016/j.jaad.2009.08.026. PMID: 19811850
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-174. http://www.ncbi.nlm.nih.gov/pubmed/?term=21306785. PMID: 21306785
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May;58(5):826-850. http://www.ncbi.nlm.nih.gov/pubmed/?term=18423260. PMID: 18423260
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Sep;61(3):451-485. http://www.ncbi.nlm.nih.gov/pubmed/?term=19493586. PMID: 19493586
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009 Apr;60(4):643-659. doi: 10.1016/j.jaad.2008.12.032. PMID: 19217694
Luba KM, Stulberg DL. Chronic plaque psoriasis. Am Fam Physician. 2006 Feb;73(4):636-644. https://www.aafp.org. PMID: 16506705
Lebwolhl M. Advances in psoriasis therapy. Dermatol Clin. 2000 Jan;18(1):13-19. http://www.ncbi.nlm.nih.gov/pubmed/10626107. PMID: 10626107
Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol. 2001 Nov;45(5):649-661. http://www.ncbi.nlm.nih.gov/pubmed/?term=11606913. PMID: 11606913
Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004 Mar;50(3):416-430. http://www.ncbi.nlm.nih.gov/pubmed/14988684. PMID: 14988684
Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001 Oct;45(4):487-498. http://www.ncbi.nlm.nih.gov/pubmed/?term=Lebwohl+M%2C+Ali+S%09%22Treatment+of+psoriasis.+Part+1.+Topical+therapy+and+phototherapy%22. PMID: 11568737
Ladizinski B, Lee KC, Wilmer E, et al. A review of the clinical variants and the management of psoriasis. Adv Skin Wound Care. 2013 Jun;26(6):271-284. http://www.ncbi.nlm.nih.gov/pubmed/?term=23669329. PMID: 23669329
Koo J, Lee E, Lee CS, et al. Psoriasis. J Am Acad Dermatol. 2004 Apr;50(4):613-622. http://www.ncbi.nlm.nih.gov/pubmed/?term=Koo+J%2C+Lee+E%2C+Lee+CS%2C+et+al%09+Psoriasis. PMID: 15034513
Kollner K, Wimmershoff MB, Hintz C, et al. Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311- nm narrowband ultraviolet B in the treatment of psoriasis. Br J Dermatol. 2005 Apr;152(4):750-754. http://www.ncbi.nlm.nih.gov/pubmed/?term=15840108. PMID: 15840108
Drew GS. Psoriasis. Prim Care. 2000 Jun;27(2):385-406. http://www.ncbi.nlm.nih.gov/pubmed/?term=Drew+GS%09Psoriasis. PMID: 10815050
Cohen SN, Baron SE, Archer CB; British Association of Dermatologists and Royal College of General Practitioners. Guidance on the diagnosis and clinical management of psoriasis. Clin Exp Dermatol. 2012 May;37(Suppl 1):13-18. doi: 10.1111/j.1365-2230.2012.04337.x. PMID: 22486764
Efalizumab (Raptiva) for treatment of psoriasis. Med Lett Drugs Ther. 2003 Dec;45(1171):97-98. PMID: 14657802
Ashcroft DM, Li Wan Po A, Williams HC, et al. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000 Apr;320(7240):963-967. http://www.ncbi.nlm.nih.gov/pubmed/?term=10753146. PMID: 10753146
Alefacept (Amevive) for treatment of psoriasis. Med Lett Drugs Ther. 2003 Apr;45(1154):31-32. PMID: 12717339
